Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bexotegrast - Pliant Therapeutics

Next Previous
Drug Profile

Bexotegrast - Pliant Therapeutics

Alternative Names: PLN-74809

Latest Information Update: 13 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pliant Therapeutics
  • Class Anti-inflammatories; Antifibrotics; Butyric acids; Naphthyridines; Quinazolines; Small molecules
  • Mechanism of Action Integrin alphavbeta1 inhibitors; Integrin alphaVbeta6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis; Primary sclerosing cholangitis
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Idiopathic pulmonary fibrosis; Primary biliary cirrhosis; Primary sclerosing cholangitis; SARS-CoV-2 acute respiratory disease

Most Recent Events

  • 13 Aug 2025 Discontinued - Phase-II for Primary sclerosing cholangitis (In adults, In the elderly) in Canada, Netherlands, Belgium (PO) (Pliant Therapeutics pipeline, August 2025)
  • 13 Aug 2025 Discontinued - Phase-II for Primary sclerosing cholangitis (In the elderly, In adults) in USA, Australia, France, United Kingdom, Austria, Germany (PO) (Pliant Therapeutics pipeline, August 2025)
  • 13 Aug 2025 Discontinued - Preclinical for Primary biliary cirrhosis in USA (PO) (Pliant Therapeutics pipeline, August 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top